%0 Case Reports
%T Are sodium-glucose cotransporter-2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation.
%A Ahangar Davoodi M
%A Daneshmand MA
%A Rezaei T
%J J Diabetes
%V 16
%N 7
%D 2024 Jul
%M 38923174
%F 4.53
%R 10.1111/1753-0407.13570
%X Highlights A persistent glycosuria alongside hypoglycemia in pediatric type 1 diabetes mellitus needs further evaluation. Morning hypoglycemia is a limiting side effect of sodium glucose transporter 2 (SGLT2) inhibitors in children younger than 5 years old. SLC5A2 mutation functioning as a SGLT2 inhibitor can result in acceptable range of glycated hemoglobin in younger children and lower required doses of insulin.